Clinical Trial: Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07650942) titled 'Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis' on June 03.

Brief Summary: The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Ulcerative Colitis (UC)

Intervention: DRUG: Hemay005 tablet

Participants receive treatment with Hemay005 tablet during the Induction Phase (week I-0~I-12).

DRUG: Placebo

Participa...